# The critical role of the coronary microcirculation in heart failure

> **NIH NIH R01** · NORTHEAST OHIO MEDICAL UNIVERSITY · 2020 · $428,993

## Abstract

The goal of this proposal is to test the hypothesis that impaired regulation of the coronary microcirculation—
more specifically, an inadequate connection between coronary blood flow and the metabolic needs of the
myocardium—underlies the development of some types of heart failure (HF). The sequence we propose is that
impaired coupling between coronary blood flow and cardiac work results in minute areas of hypoxia in cardiac
myocytes, which induces apoptosis in small numbers of cardiac myocytes. Over time these minute areas of
tissue death accumulate to an extent that cardiac function is compromised. Current treatments for heart failure
are designed to reduce cardiac work, but not directly produce coronary vasodilation. None of these therapies
stop or reverse the progression of the disease—progression is only slowed. We speculate that the reason
these treatments do not stop or reverse the progression of the disease is that they are not targeting the causal
problem of insufficient blood flow to the heart. We propose that by correcting the myocardial perfusion
deficiencies in heart failure, we will stop and potentially reverse the progression of heart failure. We propose
two aims. Aim 1 will determine if impaired regulation of myocardial blood flow, i.e., inadequate coupling of flow
to metabolism, plays a critical role in the development of heart failure. In this aim we will measure myocardial
perfusion, plasma BNP and cardiac troponin I, tissue oxygenation, cardiac metabolism and cardiac myocyte
hypoxia (using hypoxia fate mapping) and myocyte apoptosis in the murine transaortic constriction model of
heart failure. Measurements will be made at various points during the progression of the disease and in wild
type mice and mice with an impairment in myocardial blood flow (Kv1.5 null mice). These measurements will
enable precise evaluation of failure and also whether myocardial ischemia occurs during heart failure. Aim 2
will analyze if the progression of heart failure can be stopped or reversed by increasing blood flow to the heart.
In this aim we will increase blood flow to the heart by increasing expression of Kv1.5 channels in smooth
muscle or will administer a pharmacological vasodilator at varying times during the progression of the disease.
We will compare these interventions to one of the current standards of care for heart failure (beta1-adrenergic
antagonist). We will establish if increases in myocardial blood flow to the heart can stop, and/or reverse, the
progression of heart failure resulting in a better outcome than the conventional therapy. This application builds
upon the expertise of the Principal Investigator, and that of additional laboratories via subcontracts enabling
corroborative, interdisciplinary measurements to definitely test whether subtle levels of myocardial ischemia
lead to heart failure and if therapies that increase flow to the heart hold promise as a cure.

## Key facts

- **NIH application ID:** 9928485
- **Project number:** 5R01HL135024-04
- **Recipient organization:** NORTHEAST OHIO MEDICAL UNIVERSITY
- **Principal Investigator:** WILLIAM M CHILIAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $428,993
- **Award type:** 5
- **Project period:** 2017-06-01 → 2021-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9928485

## Citation

> US National Institutes of Health, RePORTER application 9928485, The critical role of the coronary microcirculation in heart failure (5R01HL135024-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9928485. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*